🇬🇧·2d agoResearch
AXL–SHC1 signaling axis mediates adaptive resistance to HER2-targeted tyrosine kinase inhibitors in HER2-aberrant lung and gastric cancers
Publisher
n
npj Precision Oncology
UK
This page provides a limited summary and publisher metadata to support discovery before sending readers to the original article.
Read originalIn-platform summary, original article off-platform
This page presents the title, publisher metadata, and a limited summary excerpt to help users judge relevance first. Full-text reading stays on the publisher's original site.
Source route
Continue on nature.com
Leave the platform to read the original full article on the publisher site.
Source: npj Precision Oncology
Scope: Research
Related coverage
More related coverage
npj Precision Oncology·1d ago
Profiling KRAS mutations in whole blood by error-corrected maximum depth sequencing
Dana-Farber Cancer Institute·1d ago
Dana-Farber Preclinical Research Finds Opportunities for Treatment Improvements for HER2-positive Breast Cancer
Drugs that target human epidermal growth factor receptor 2 (HER2) have revolutionized the treatment...
npj Precision Oncology·2d ago
Multimodal AI model for early detection of hepatocellular carcinoma
Science·18h ago